What is the recommended initial management and work‑up for a patient with an absolute eosinophil count of 15.3 × 10⁹/L?

Immediate Management for Severe Hypereosinophilia (AEC 15.3 × 10⁹/L)

This patient requires urgent hematology referral and expedited evaluation for non-infectious causes, particularly malignancy and hypereosinophilic syndromes, as an AEC >30,000/µL is rarely due to parasitic infection. 1

Critical Context

Your patient has severe hypereosinophilia (AEC 15,300 cells/µL = 15.3 × 10⁹/L), which exceeds the standard threshold of 5 × 10⁹/L and approaches the level where parasitic causes become exceedingly unlikely. At this level, the differential shifts dramatically toward primary (clonal) eosinophilia, hypereosinophilic syndrome (HES), and hematologic malignancies 1.

Immediate Assessment Priorities

1. Assess for End-Organ Damage (URGENT)

Look specifically for:

• Cardiac involvement: Check troponin, BNP, ECG, and echocardiogram (myocarditis and endomyocardial fibrosis are life-threatening complications)
• Pulmonary: Chest imaging for infiltrates, assess for dyspnea/cough
• Neurologic: Peripheral neuropathy, encephalopathy, thromboembolic events
• Dermatologic: Urticarial rash, angioedema
• Gastrointestinal: Diarrhea, abdominal pain

This is critical because eosinophil-mediated organ damage determines urgency of treatment 2, 3.

2. Travel and Exposure History

Despite the high AEC making parasites less likely, you must still ask:

• Recent travel to endemic regions (Africa, Southeast Asia, Latin America) within past 2-8 weeks
• Freshwater exposure (schistosomiasis/Katayama syndrome can cause AEC >5 × 10⁹/L) 4
• Immigration status from helminth-endemic areas

However, at AEC 15.3 × 10⁹/L, only 2 patients in a large NIH cohort had parasitic infections at levels >30 × 10⁹/L (both children with visceral larva migrans), and parasitic diagnoses decrease significantly as AEC rises above this range 1.

Diagnostic Workup Algorithm

First-Tier Tests (Order Immediately)

1. Hematologic evaluation:

   • Peripheral blood smear review (look for blasts, dysplasia, abnormal eosinophils)
   • Flow cytometry for aberrant T-cell populations (lymphocyte-variant HES)
   • Serum tryptase (systemic mastocytosis)
   • Vitamin B12 level (often elevated in myeloproliferative neoplasms)

2. Molecular/cytogenetic testing (CRITICAL):

   • FIP1L1-PDGFRA fusion (most important—imatinib-responsive)
   • PDGFRB and FGFR1 rearrangements
   • PCM1-JAK2 fusion
   • These are essential because PDGFRA/PDGFRB-positive disease responds dramatically to imatinib 2

3. Parasitic screening (despite low probability):

   • Strongyloides serology (high-yield, critical to exclude before immunosuppression)
   • Schistosoma serology
   • Concentrated stool microscopy × 3
   • Stool PCR if available 4

4. Baseline organ function:

   • Troponin, BNP, ECG, echocardiogram
   • Chest X-ray or CT
   • Liver function tests

Second-Tier Tests (Based on Initial Results)

• Bone marrow biopsy with cytogenetics if primary eosinophilia suspected
• T-cell receptor gene rearrangement studies if aberrant T cells detected
• Tissue biopsy of affected organs (skin, lung, GI tract) if single-organ involvement suspected
• IgE level (highly variable and NOT diagnostically useful for distinguishing causes) 1

Treatment Approach

If Symptomatic or Organ Involvement Present:

1. PDGFRA/PDGFRB-positive disease: Imatinib 100-400 mg daily (exquisitely responsive) 2

2. Lymphocyte-variant HES or idiopathic HES:

   • Corticosteroids (prednisone 1 mg/kg/day) as first-line 2
   • Hydroxyurea or interferon-alfa for steroid-refractory cases
   • Consider mepolizumab (anti-IL-5) for steroid-dependent cases

3. If parasitic infection confirmed:

   • Acute schistosomiasis: Corticosteroids ± albendazole, then praziquantel at 8 weeks 4
   • Strongyloidiasis: Ivermectin 200 µg/kg (ONLY after excluding Loa loa if travel to endemic regions) 4

If Asymptomatic with No Organ Involvement:

• Do NOT adopt "watch and wait" at this AEC level—this is appropriate only for mild eosinophilia <1.5 × 10⁹/L 2
• Proceed with full diagnostic workup while monitoring closely
• Consider empirical antiparasitic treatment (albendazole 400 mg + ivermectin 200 µg/kg) ONLY if travel history strongly suggests helminth exposure AND after excluding Loa loa 4

Key Pitfalls to Avoid

1. Delaying cardiac evaluation: Eosinophil-mediated cardiac damage can be irreversible
2. Starting ivermectin without excluding Loa loa: Can cause fatal encephalopathy in co-infected patients 4
3. Assuming parasites at this AEC level: The higher the count, the less likely it's parasitic 1
4. Missing PDGFRA/PDGFRB testing: These patients have curative treatment with imatinib 2
5. Relying on IgE levels: These are not diagnostically useful 1

Referral Threshold

Immediate hematology referral is mandatory at AEC 15.3 × 10⁹/L. Recent data supports that AEC ≥1.5 × 10⁹/L warrants hematology evaluation, with 97% sensitivity for clinically meaningful eosinophilia requiring treatment 5. Your patient is 10-fold above this threshold.